Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 1.070-1.200 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. Simulations Plus also updated its FY25 guidance to $1.07-$1.20 EPS.

Simulations Plus Stock Up 4.4 %

Shares of NASDAQ:SLP traded up $1.29 during trading on Tuesday, hitting $30.39. 503,863 shares of the stock traded hands, compared to its average volume of 303,448. The company has a fifty day moving average price of $29.78 and a two-hundred day moving average price of $34.16. Simulations Plus has a 52-week low of $27.07 and a 52-week high of $51.22. The company has a market cap of $610.38 million, a price-to-earnings ratio of 62.02 and a beta of 0.80.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The business had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same quarter in the prior year, the firm posted $0.18 earnings per share. The company’s revenue was up 19.9% compared to the same quarter last year. On average, equities research analysts predict that Simulations Plus will post 1.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SLP has been the subject of a number of research analyst reports. BTIG Research reduced their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Thursday, October 24th. Stephens initiated coverage on shares of Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 target price for the company. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, William Blair reiterated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Simulations Plus has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Insider Buying and Selling at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the transaction, the director now owns 3,442,584 shares in the company, valued at $109,336,467.84. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 19.40% of the stock is owned by insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.